Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 7:04 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1873–1896 of 3,917 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Prostate Cancer Clear all

Conditions: Small Cell Lung Cancer Metastatic or Locally Advanced, Neuroendocrine Cancer, Metastatic Neuroendocrine Prostate Cancer, Metastatic Advanced Poorly Differentiated Gastroenteropancreatic Neuroendocrine Carcinoma, Metastatic Advanced Merkel Cell Carcinoma, Locally Advanced Large Cell Neuroendocrine Carcinoma of the Lung, Locally Advanced Extrapulmonary Neuroendocrine Carcinoma, Locally Advanced Neuroendocrine Prostate Cancer, Locally Advanced Poorly Differentiated Gastroenteropancreatic Neuroendocrine, Locally Advanced Merkel Cell Carcinoma, Metastatic Large Cell Neuroendocrine Carcinoma of the Lung
Interventions: BL-M14D1; Drug
Lead sponsor: SystImmune Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 24
States / cities: Huntsville, Alabama • Glendale, California • Long Beach, California + 18 more

Conditions: Breast Cancer, Colorectal Cancer, Lung Cancer, Prostate Cancer
Interventions: Questionnaire; Behavioral
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 4
States / cities: Houston, Texas

Conditions: Castration-Sensitive Prostate Carcinoma, Metastatic Prostate Adenocarcinoma, Stage IVB Prostate Cancer AJCC v8
Interventions: Abiraterone, Biospecimen Collection, Bone Scan, Computed Tomography, Docetaxel, Enzalutamide, FDG-Positron Emission Tomography, Magnetic Resonance Imaging, PSMA PET Scan, Vudalimab; Drug · Procedure
Lead sponsor: Emory University; Other
Eligibility: 18 Years and older · Male only
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 2
States / cities: Atlanta, Georgia

Conditions: Metastatic Prostate Cancer
Interventions: AZD0754, AZD2287; Biological
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years · Male only
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 13
States / cities: Duarte, California • Tampa, Florida • Atlanta, Georgia + 8 more

Conditions: Prostate Cancer
Interventions: selenomethionine, finasteride, placebo; Dietary Supplement · Drug · Other
Lead sponsor: Roswell Park Cancer Institute; Other
Eligibility: 18 Years and older · Male only
Enrollment: 55 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2012
U.S. locations: 1
States / cities: Buffalo, New York

Conditions: Prostate Cancer
Interventions: Sonoelastography; Device
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older · Male only
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Prostate Cancer
Interventions: AS1404 (DMXAA); Drug
Lead sponsor: Antisoma Research; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2008
U.S. locations: 27
States / cities: Alhambra, California • Bakersfield, California • Burbank, California + 23 more

Conditions: Recurrent Prostate Carcinoma, Stage III Prostate Adenocarcinoma AJCC v7, Stage IV Prostate Adenocarcinoma AJCC v7
Interventions: Apalutamide, External Beam Radiation Therapy, Placebo Administration; Drug · Radiation · Other
Lead sponsor: NRG Oncology; Other
Eligibility: 18 Years and older · Male only
Enrollment: 298 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2030
U.S. locations: 352
States / cities: Gilbert, Arizona • Peoria, Arizona • Scottsdale, Arizona + 251 more

Conditions: Prostatic Neoplasms
Interventions: Pembrolizumab, Enzalutamide, Placebo; Biological · Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 1,244 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2026
U.S. locations: 28
States / cities: Mobile, Alabama • Fullerton, California • Los Angeles, California + 25 more

Conditions: Neoplasms, Prostate Cancer, Lung Cancer, Breast Cancer, Colon Cancer
Interventions: ETBX-051; adenoviral brachyury vaccine, ETBX-061; adenoviral Mucin-1 (MUC1) vaccine, ETBX-011; adenoviral Carcinoembryonic antigen (CEA) vaccine; Biological
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 100 Years
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Prostatic Neoplasms, Breast Neoplasms, Colorectal Neoplasms, Melanoma, Leukemia
Interventions: Interactive Voice Response (IVR) Reminders; Behavioral
Lead sponsor: Michigan State University; Other
Eligibility: 21 Years and older
Enrollment: 322 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 8
States / cities: New Haven, Connecticut • Chicago, Illinois • Indianapolis, Indiana + 4 more

Conditions: Recurrent Prostate Cancer
Interventions: ADXS-504; Drug
Lead sponsor: Mark Stein; Other
Eligibility: 18 Years to 99 Years · Male only
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 1
States / cities: New York, New York

Conditions: Metastatic Castration-Resistant Prostate Adenocarcinoma
Interventions: CCW702; Drug
Lead sponsor: Calibr, a division of Scripps Research; Other
Eligibility: 18 Years and older · Male only
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 5
States / cities: San Diego, California • Baltimore, Maryland • Detroit, Michigan + 2 more

Conditions: Prostate Cancer, Bladder Cancer
Interventions: PET/MRI; Procedure
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years and older
Enrollment: 21 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2016
U.S. locations: 1
States / cities: New York, New York

Conditions: Lung Cancer, Malnutrition, Pancreatic Cancer, Prostate Cancer, Weight Changes
Interventions: Medical nutrition therapy, Standard Care; Behavioral
Lead sponsor: Rutgers, The State University of New Jersey; Other
Eligibility: 18 Years to 120 Years
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 1
States / cities: New Brunswick, New Jersey

Conditions: Prostate Cancer
Interventions: Observation; Other
Lead sponsor: BioProtect; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 2
States / cities: Campbell, California • Reno, Nevada

Conditions: Prostate Cancer
Interventions: leuprolide acetate; Drug
Lead sponsor: GP-Pharm; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 8
States / cities: New Port Richey, Florida • Lawrenceville, New Jersey • Poughkeepsie, New York + 5 more

Conditions: Prostate Cancer
Interventions: Cytalux™ (pafolacianine) for fluorescent imaging, Image Guided Surgery; Drug · Procedure
Lead sponsor: Indiana University; Other
Eligibility: 18 Years and older · Male only
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 3
States / cities: Carmel, Indiana • Indianapolis, Indiana

Conditions: Prostate Cancer
Interventions: APC-100; Drug
Lead sponsor: Adamis Pharmaceuticals Corporation; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2017
U.S. locations: 2
States / cities: Detroit, Michigan • Madison, Wisconsin

Conditions: Prostate Cancer, Bone Metastases, Prostate Neoplasms
Interventions: LHRH agonist/antagonist, Bicalutamide, Radium-223 dichloride; Drug · Radiation
Lead sponsor: Ajjai Alva, MD; Other
Eligibility: 18 Years and older · Male only
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 12
States / cities: Phoenix, Arizona • Peoria, Illinois • Indianapolis, Indiana + 8 more

Conditions: Castrate Resistant Prostate Cancer, NUT Carcinoma, Chronic Myelomonocytic Leukemia, Myelofibrosis
Interventions: EP31670; Drug
Lead sponsor: Epigenetix, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 6
States / cities: Phoenix, Arizona • Jacksonville, Florida • Boston, Massachusetts + 3 more

Conditions: Cancer
Interventions: Experimental: Mentored Gardening Intervention; Behavioral
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 60 Years and older
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Prostate Cancer
Interventions: Triptorelin pamoate, Leuprolide acetate; Drug
Lead sponsor: Watson Pharmaceuticals; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 118 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 16
States / cities: Homewood, Alabama • Daytona Beach, Florida • Orange City, Florida + 13 more

Conditions: Prostate Cancer
Interventions: Dupilumab; Drug
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 18 Years and older · Male only
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Baltimore, Maryland

Search by objective public record fields.

Evaluating BL-M14D1 in Subjects With Locally Advanced or Metastatic Small Cell Lung Cancer and Neuroendocrine Tumors

Ambulatory Cancer Pain Management: A Feasibility Study

Vudalimab (XmAb20717) in Combination With Standard of Care Treatment in Patients With Metastatic Castration Sensitive Prostate Cancer

Study of AZD0754 in Participants With Metastatic Prostate Cancer

Selenomethionine and Finasteride Before Surgery or Radiation Therapy in Treating Patients With Stage I or Stage II Prostate Cancer

A Pilot Trial of Sonoelastography for Planning Tumor-targeted Prostate Biopsy

Study of AS1404 With Docetaxel in Patients With Hormone Refractory Metastatic Prostate Cancer

Radiation Therapy With or Without Apalutamide in Treating Patients With Recurrent Prostate Cancer, the BALANCE Trial

Study of Pembrolizumab (MK-3475) Plus Enzalutamide Versus Placebo Plus Enzalutamide in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-3475-641/KEYNOTE-641)

Multi-Targeted Recombinant Ad5 (CEA/MUC1/Brachyury) Based Immunotherapy Vaccine Regimen in People With Advanced Cancer

Improving Adherence to Oral Cancer Agents and Self Care of Symptoms Using an IVR

Study of ADXS-504 Immunotherapy for Recurrent Prostate Cancer

First-in-human Study of CCW702 in Patients With Metastatic Castration Resistant Prostate Cancer

Use of PET/MRI Tracer to Further Understanding of Prostate Cancer Development

Medical Nutrition Therapy or Standard Care in Treating Patients With Lung Cancer, Pancreatic Cancer, or Stage III or Stage IV Prostate Cancer

Prospective Evaluation of a Commercially Available Hydrogel Spacer

Efficacy and Safety Study of a New Leuprolide Acetate 17 mg Depot to Treat Prostate Cancer Patients

CYTALUX™for the Intraoperative Imaging of Prostate Cancer

Dose-Escalation and Safety Study of APC-100 for the Treatment of Prostate Cancer

Androgen Deprivation Therapy +/- Radium-223 Dichloride in Metastatic Prostate Cancer With Bone Metastases

Dual BET and CBP/p300 Inhibitor in Patients With Targeted Advanced Solid Tumors and Hematological Malignancies

Vegetable Garden Feasibility Trial to Promote Function in Older Cancer Survivors

Randomized Crossover Trial to Assess the Tolerability of Gonadotropin Releasing Hormone (GnRH) Analogue Administration

Neoadjuvant Dupilumab in Men With Localized High-Risk Prostate Cancer